News Releases

2010
2009
2008
2007
2006
2005
2004

Dec 14, 2005 Protox files IND for the treatment of prostate cancer
Dec 12, 2005 Protox files foundation patent for PORxin™ technology
Dec 6, 2005 Protox Therapeutics Named to 2005 TSX Venture 50
Nov 29, 2005 Protox releases 3rd Quarter, 2005 financial statements
Nov 24, 2005 Protox appoints Dr. James Miller to its Board of Directors
Nov 17, 2005 Protox Completes Oversubscribed $5.8 Million Equity Financing
Nov 7, 2005 Protox Completes Oversubscribed $4.5 Million Equity Financing
Oct 27, 2005 Protox Announces $4.0 Million Equity Financing
Oct 20, 2005 Protox Receives IRB Approval to Conduct Clinical Testing of PRX302 at a Leading U.S. Hospitals
Sep 21, 2005 Protox Reports Completion of Pre-Clinical Studies for Lead Drug to Support Phase 1 Human Clinical Trials
Aug 26, 2005 Protox releases 2nd Quarter, 2005 financial statements
Aug 9, 2005 Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study
July 13, 2005 Protox appoints Vice President, Business Development
June 29, 2005 Protox strengthens senior management team
June 16, 2005 Protox files patent for treatment of Benign Prostatic Hyperplasia
June 7, 2005 Protox receives funding from NRC to develop lung cancer drug
May 30, 2005 Protox releases 1st Quarter, 2005 financial statements
Apr 26, 2005 Protox releases 2004 financial statements
Apr 20, 2005 Protox reports efficacy data of prostate cancer drug in animals
Apr 18, 2005 Protox Announces Change to Senior Management
Apr 14, 2005 Protox Efficacy Data to be Presented at Leading Cancer Research Conference
Apr 5, 2005 Protox exercises Lung Cancer Licence option with the NRC Institute for Biological Sciences and with the University of Victoria
Mar 2, 2005 Protox appoints Fahar Merchant as Vice President, Corporate Development
Feb 23, 2005 Protox Chief Scientific Officer wins Entrepreneurship Award
Jan 11, 2005 Protox Achieves milestone towards an IND Filing

What's New

August 11, 2010
Protox Reports Second Quarter 2010 Financial Results

June 2, 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

 

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

 

Stock Quote

LAST TRADE:$0.37
TRADE TIME:3:58PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.37
OPEN:$0.36
BID:$0.36
ASK:$0.37